Adrenergic Mediation of Hypoglycemia-Associated Autonomic Failure

Ranjani Ramanathan and Philip E. Cryer

OBJECTIVE—We tested the hypothesis that adrenergic activation, cholinergic activation, or both, mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans.

RESEARCH DESIGN AND METHODS—Seventeen healthy adults were studied on 2 consecutive days on three occasions. Day 1 involved hyperinsulinemic euglycemic (90 mg/dL × 1 h), then hypoglycemic (54 mg/dL × 2 h) clamps, in the morning and afternoon on all three occasions with 1) saline infusion, 2) adrenergic blockade with the nonselective β-adrenergic and β-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade plus cholinergic blockade with the muscarinic cholinergic antagonist atropine in random sequence. Day 2 involved similar morning euglycemic and hypoglycemic clamps, with saline infusion, on all three occasions.

RESULTS—Compared with the responses to hypoglycemia during saline infusion on day 1, the plasma epinephrine and norepinephrine responses to hypoglycemia were reduced on day 2 (351 ± 13 vs. 214 ± 22 pg/mL for epinephrine and 252 ± 4 vs. 226 ± 7 pg/mL for norepinephrine during the last hour; both P < 0.0001). However, the plasma epinephrine and norepinephrine responses to hypoglycemia were not reduced on day 2 when adrenergic or adrenergic plus cholinergic blockade was produced during hypoglycemia on day 1.

CONCLUSIONS—Adrenergic blockade prevents the effect of hypoglycemia to reduce the plasma catecholamine responses to subsequent hypoglycemia. Thus, adrenergic activation mediates the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of hypoglycemia-associated autonomic failure in diabetes, in humans. Diabetes 60:602–606, 2011

Iatrogenic hypoglycemia is the limiting factor in the glycemic management of diabetes (1). It causes recurrent morbidity in most people with type 1 diabetes and in many with type 2 diabetes, and is sometimes fatal, impairs physiologic and behavioral defenses against subsequent hypoglycemia, and generally precludes maintenance of euglycemia over a lifetime of diabetes. The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes posits that recent antecedent hypoglycemia, as well as prior exercise or sleep, causes both the syndrome of defective glucose counterregulation (by reducing the adrenomedullary epinephrine response to subsequent hypoglycemia in the setting of absent decrements in insulin and absent increments in glucagon) and of hypoglycemia unawareness (by reducing the sympathoadrenal and resulting neurogenic symptom responses to subsequent hypoglycemia) (1–4). These two components of HAAF are both associated with a substantially increased incidence of hypoglycemia during intensive therapy for diabetes (1). Perhaps the most compelling evidence of the clinical effect of HAAF is the finding, originally in three independent laboratories (5–8), that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycemia reverses hypoglycemia unawareness and improves the attenuated epinephrine component of defective glucose counterregulation in most affected patients.

The mechanisms of the attenuated sympathoadrenal response to hypoglycemia, the key feature of the pathogenesis of HAAF in diabetes (1–8), are unknown (1). Although much of the neuroscience research into this issue has focused on the hypothalamus (9), recent translational research has raised the possibility that a complex cerebral network normally regulates the hypothalamic (and thus the systemic sympathoadrenal) response to falling plasma glucose concentrations (10–12) and that an inhibitory signal mediated through the thalamus might be involved in the pathogenesis of HAAF (12).

Hypoglycemia activates the sympathoadrenal system (1,13,14). This includes the release of catecholamines that interact with β-adrenergic and β-adrenergic receptors—norepinephrine from sympathetic postganglionic neurons and epinephrine and norepinephrine from the adrenal medullae—and acetylcholine that interacts with muscarinic cholinergic receptors—from sympathetic postganglionic neurons. Hypoglycemia also activates central nervous system circuits, including those that involve adrenergic and cholinergic neurotransmission. There are, of course, an array of other neurotransmitters released in the peripheral and the central nervous systems.

We used the original model of HAAF (2) and the nonselective β-adrenergic and β-adrenergic antagonists phentolamine and propranolol as well as the muscarinic cholinergic antagonist atropine in doses shown previously to be both safe and effective (15) to test the hypothesis that adrenergic activation, cholinergic activation, or both, mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of HAAF in diabetes (1–8), in humans.

RESEARCH DESIGN AND METHODS
This study was approved by the Washington University Human Research Protection Office and was conducted at the Washington University Clinical Research Unit (CRU).

Participants. Study participants comprised 17 adults (7 women, 10 men), with a mean (± SD) age of 29 ± 5 years and a BMI of 26.5 ± 4.6 kg/m², who gave...
their written consent. They were in good health as determined by medical history, physical examination, and fasting plasma glucose and creatinine concentrations, hematoctrits, and electrocardiograms that were within normal reference ranges.

**Experimental design.** Participants were studied on 2 consecutive days on three occasions, separated by at least 2 weeks, after overnight fasts. Intravenous catheters were inserted into a hand vein, with that hand kept in a ~55°C plexiglas box for arterialized venous blood sampling, and into a contralateral antecubital vein for insulin, glucose, and drug infusions and injections.

Day 1 involved hyperinsulinemic (2.0 mU/kg/min), euglycemic (90 mg/dL [5.0 mmol/L] × 1 h), and then hypoglycemic (54 mg/dL [3.0 mmol/L] × 2 h) clamps in the morning and again in the afternoon on all three occasions. Intravenous infusions during these day 1 glucose clamps were 1) saline, 2) the nonselective α-adrenergic receptor antagonist phentolamine mesylate (70 μg/kg, followed by 7.0 μg/kg/min) and the nonselective β-adrenergic antagonist propranolol hydrochloride (14 μg/kg, followed by 1.4 μg/kg/min), or 3) phentolamine plus propranolol and the muscarinic cholinergic antagonist atropine (1.0 mg injected intravenously at the end of each euglycemic clamp and 60 min into each hypoglycemic clamp) in random sequence. This experimental design is illustrated, with the actual plasma glucose concentration data, in Fig. 1.

Plasma glucose concentrations were measured every 5 min at the bedside (YSI Glucose Analyzer, Yellow Springs Instruments, Yellow Springs, OH) to guide 20% glucose infusions. Heart rates and blood pressures (GE Dash 3000, Fairfield, CT) were recorded at 15-min intervals, and the electrocardiogram was monitored throughout. Arterialized venous samples for the additional analytes detailed below were drawn at 15-min intervals during the morning euglycemic and hypoglycemic clamps on both days. This model of morning and afternoon hypoglycemia reduces the sympathoadrenal response to hypoglycemia the following day (1–4), and these doses of phentolamine, propranolol, and atropine are safe and hemodynamically, metabolically, and symptomatically effective (15).

Day 2 involved identical hyperinsulinemic euglycemic and then hypoglycemic clamps, with saline infusion, in the morning on all three occasions. Arterialized venous samples were again used to measure plasma glucose concentrations every 5 min and were drawn for the analytes detailed subsequently every 15 min.

**Analytic methods.** Plasma glucose concentrations were measured with a glucose oxidase method (YSI Glucose Analyzer). Plasma insulin, C-peptide, growth hormone, and cortisol concentrations were measured with two-site derivative (radioenzymatic) method (16).

Plasma glucagon and pancreatic polypeptide concentrations were measured with a glucose oxidase method (YSI Glucose Analyzer). Plasma epinephrine and norepinephrine concentrations were measured with a high-performance liquid chromatography method (17). Increments in plasma epinephrine and norepinephrine concentrations during the hypoglycemic clamps on both days. This model of morning and afternoon hypoglycemia reduces the sympathoadrenal response to hypoglycemia the following day (1–4), and these doses of phentolamine, propranolol, and atropine are safe and hemodynamically, metabolically, and symptomatically effective (15).

**RESULTS**

**Plasma glucose concentrations, day 1 and day 2.** Plasma glucose concentrations were clamped at euglycemic (~90 mg/dL [5.0 mmol/L]) and then hypoglycemic (~54 mg/dL [3.0 mmol/L]) levels in the morning and again in the afternoon—with intravenous infusions of saline, phentolamine plus propranolol (adrenergic blockade), or phentolamine plus propranolol with injection of atropine (adrenergic plus cholinergic blockade)—on day 1 and on the morning of day 2—with intravenous infusion of saline—after saline, phentolamine plus propranolol, or phentolamine plus propranolol with atropine on day 1 on three separate occasions (Fig. 1). The glucose infusion rates required to maintain the clamps were similar on all occasions (data not shown).

**Responses on day 1.** Compared with those during saline, increments in plasma epinephrine and norepinephrine concentrations during hypoglycemia were increased about threefold during adrenergic blockade and during adrenergic plus cholinergic blockade (both P < 0.0001; Fig. 2). The final epinephrine values were 352 ± 46 pg/mL (1,920 ± 251 pmol/L), 1,040 ± 160 pg/mL (5,680 ± 873 pmol/L), and 1,130 ± 193 pg/mL (6,170 ± 1,050 pmol/L), respectively. The final norepinephrine values were 257 ± 19 pg/mL (1.52 ± 0.11 nmol/L), 809 ± 84 pg/mL (4.78 ± 0.50 nmol/L), and 786 ± 100 pg/mL (4.65 ± 0.59 nmol/L), respectively. Increments in plasma pancreatic polypeptide concentrations during hypoglycemia were similar during saline and during adrenergic blockade but were prevented during adrenergic plus cholinergic blockade. The final pancreatic polypeptide values were 356 ± 45 pg/mL (85 ± 11 pmol/L), 374 ± 42 pg/mL (89 ± 10 pmol/L), and 75 ± 9 pg/mL (18 ± 2 pmol/L), respectively.
Plasma concentrations of infused insulin stabilized at ~95 μU/mL (570 pmol/L) during infusion of saline but rose to ~120 μU/mL (720 pmol/L) during adrenergic blockade and during adrenergic plus cholinergic blockade (both P < 0.0001; Fig. 3). The final insulin values were 96 ± 8 μU/mL (576 ± 48 pmol/L), 122 ± 12 μU/mL (732 ± 72 pmol/L), and 123 ± 9 μU/mL (738 ± 54 pmol/L), respectively. Increments in plasma glucagon concentrations during hypoglycemia were similar on all three occasions (Fig. 3). The final glucagon values were 98 ± 11 pg/mL (28 ± 3 pmol/L), 110 ± 10 pg/mL (32 ± 3 pmol/L), and 104 ± 7 pg/mL (30 ± 2 pmol/L), respectively.

Compared with those during saline, increments in plasma growth hormone and cortisol concentrations during hypoglycemia were increased during adrenergic blockade and adrenergic plus cholinergic blockade (P < 0.0001 under both conditions for both hormones; Fig. 3). The final growth hormone values were 13.3 ± 2.2 ng/mL (587 ± 97 pmol/L), 25.2 ± 3.2 ng/mL (1,110 ± 141 pmol/L), and 20.7 ± 2.8 ng/mL (914 ± 124 pmol/L), respectively. The final cortisol values were 18.4 ± 1.5 μg/dL (508 ± 41 nmol/L), 22.1 ± 1.4 μg/dL (610 ± 39 nmol/L), and 23.7 ± 1.6 μg/dL (654 ± 44 nmol/L), respectively.

Heart rate responses to hypoglycemia were decreased during adrenergic blockade and increased during adrenergic plus cholinergic blockade compared with those during saline (both P < 0.0001; Table 1). Systolic and diastolic blood pressures were reduced during adrenergic blockade and during adrenergic plus cholinergic blockade (both P < 0.0001; Table 1).

**Responses on day 2 compared with those during saline on day 1.** Compared with that during saline on day 1, the increment in the plasma epinephrine concentration during hypoglycemia was attenuated by ~50% on day 2 (P < 0.0001; Fig. 4). The epinephrine values during the last hour of hypoglycemia were 359 ± 26 pg/mL (1,960 ± 142 pmol/L) and 375 ± 11 pg/mL (2,050 ± 60 pmol/L), respectively.

Similarly, the increment in the plasma norepinephrine concentration during hypoglycemia was attenuated on day 2 compared with that during saline on day 1 (P < 0.0001; Fig. 4). The norepinephrine values during the last hour of hypoglycemia were 252 ± 4 pg/mL (1.49 ± 0.02 nmol/L) and 226 ± 7 pg/mL (1.34 ± 0.04 nmol/L), respectively. The increments in plasma norepinephrine during hypoglycemia were not reduced on day 2 after adrenergic blockade or adrenergic plus cholinergic blockade on day 1 (Fig. 4). The norepinephrine values during the last hour of hypoglycemia were 284 ± 11 pg/mL (1.68 ± 0.06 nmol/L) and 256 ± 11 pg/mL (1.51 ± 0.06 nmol/L), respectively. Compared with that during saline on day 1, the increment in the plasma pancreatic polypeptide concentration during hypoglycemia was attenuated by ~50% on day 2 under all three study conditions (P < 0.0001; Fig. 4). The pancreatic polypeptide values during the last hour of hypoglycemia were 373 ± 6 pg/mL (89 ± 1 pmol/L) on day 1 and 216 ± 7 pg/mL (52 ± 2 pmol/L), 214 ± 17 pg/mL (51 ± 4 pmol/L), and 239 ± 10 pg/mL (57 ± 2 pmol/L), respectively, on day 2.

Plasma concentrations of infused insulin were stable and comparable to those during saline on day 1 during all three hyperinsulinemic euglycemic and hypoglycemic clamps on day 2 (Fig. 5). Compared with that during saline on day 1, the increments in the plasma glucagon concentrations during hypoglycemia were reduced under all three conditions on day 2 (P = 0.0263, 0.0008 and <0.0001, respectively; Fig. 5). The glucagon values during the last hour of hypoglycemia during saline infusion on day 1 were 99 ± 1 pg/mL (28 ± 0 pmol/L). The glucagon values during the last hour of hypoglycemia on day 2 were 89 ± 3 pg/mL (26 ± 1 pmol/L), 83 ± 2 pg/mL (24 ± 1 pmol/L), and 86 ± 2 pg/mL (25 ± 1 pmol/L) after saline, adrenergic blockade, and adrenergic plus cholinergic blockade on day 1, respectively. This was also the case for increments in the plasma cortisol concentrations during hypoglycemia on day 2 (P = 0.0001, <0.0001 and 0.0030) (Fig. 5). The cortisol values during the last hour of hypoglycemia during saline infusion on day 1 were 17.3 ± 0.7 μg/dL (480 ± 19 nmol/L). Cortisol values during the last hour of hypoglycemia on day 2 were 14.2 ± 0.6 μg/dL (390 ± 17 nmol/L), 13.5 ± 1.0 μg/dL (370 ± 28 nmol/L), and 15.0 ± 1.1 μg/dL (410 ± 30 nmol/L) after saline, adrenergic blockade, and adrenergic plus cholinergic blockade on day 1, respectively. Compared with that during saline on day 1, the increment in the plasma growth hormone concentration during hypoglycemia was reduced on day 2 (P = 0.0028; Fig. 5). The growth hormone values during the last hour of hypoglycemia were 12.6 ± 0.5 ng/mL (560 ± 22 pmol/L) on day 1 and 7.7 ± 0.2 ng/mL (340 ± 9 pmol/L) on day 2. In contrast, growth hormone values during the last hour of hypoglycemia on day 2 were not reduced after adrenergic blockade or adrenergic plus cholinergic blockade on day 1 – 10.8 ± 0.8 ng/mL (480 ± 35 pmol/L) and 14.0 ± 1.4 ng/mL (620 ± 62 pmol/L), respectively.

**DISCUSSION**

We used a well-documented model of HAAF in diabetes (hypoglycemia attenuates the sympathoadrenal response to hypoglycemia the following day) (1–4) and the classic adrenergic and cholinergic antagonists phentolamine, atropine, and propranolol with atropine (Δ) on day 1. The P values represent comparisons with the values during saline, both P < 0.0001 for insulin, growth hormone, and cortisol.

**FIG. 3.** Mean (± SE) plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps with intravenous infusions of saline (○), phentolamine plus propranolol (□), or phentolamine plus propranolol with atropine (△) on day 1. The P values represent comparisons with the values during saline, both P < 0.0001 for insulin, growth hormone, and cortisol.
propranolol and atropine (13–15) to test the hypothesis that adrenergic activation, cholinergic activation, or both, mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of HAAF in diabetes (1–8), in humans.

The data indicate that adrenergic mechanisms mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia. Morning and afternoon hypoglycemia with saline infusion on day 1 led to attenuated increments in plasma epinephrine and norepinephrine concentrations, markers of the sympathoadrenal, primarily adrenomedullary, response to hypoglycemia (17), during hypoglycemia on day 2. Thus, the phenomenon that we sought to explore mechanistically—recent antecedent hypoglycemia reduces the sympathoadrenal response to subsequent hypoglycemia (1–8)—was reproduced.

However, when adrenergic blockade (without or with cholinergic blockade) was produced during hypoglycemia on day 1, the increments in plasma epinephrine and norepinephrine concentrations during hypoglycemia on day 2 were not attenuated. Thus, combined adrenergic blockade with the nonselective α-adrenergic antagonist phentolamine and the nonselective β-adrenergic antagonist propranolol prevented the effect of hypoglycemia to reduce the

**TABLE 1**

Heart rate and blood pressure responses on day 1 during clamped hyperinsulinemic euglycemia (0800–0900 h) and hypoglycemia (0900–1100 h)

| Clock time | HR (bpm) | sBP (mmHg) | dBP (mmHg) | HR (bpm) | sBP (mmHg) | dBP (mmHg) | HR (bpm) | sBP (mmHg) | dBP (mmHg) |
|------------|----------|------------|------------|----------|------------|------------|----------|------------|------------|
| 0745 h     | 69 ± 2   | 125 ± 3    | 72 ± 2     | 69 ± 2   | 120 ± 3    | 68 ± 2     | 67 ± 3   | 119 ± 3    | 67 ± 2     |
| 0800 h     | 68 ± 2   | 125 ± 3    | 71 ± 2     | 70 ± 2   | 118 ± 4    | 66 ± 2     | 69 ± 3   | 118 ± 3    | 68 ± 2     |
| 0815 h     | 70 ± 2   | 124 ± 3    | 70 ± 3     | 71 ± 2   | 117 ± 3    | 63 ± 2     | 71 ± 3   | 114 ± 3    | 64 ± 2     |
| 0830 h     | 71 ± 3   | 123 ± 3    | 70 ± 3     | 72 ± 2   | 115 ± 3    | 60 ± 1     | 69 ± 3   | 112 ± 3    | 64 ± 2     |
| 0845 h     | 70 ± 2   | 124 ± 3    | 70 ± 2     | 69 ± 2   | 112 ± 3    | 60 ± 2     | 69 ± 2   | 111 ± 3    | 60 ± 2     |
| 0900 h     | 71 ± 2   | 124 ± 3    | 68 ± 2     | 68 ± 2   | 113 ± 3    | 58 ± 1     | 77 ± 4   | 112 ± 3    | 59 ± 2     |
| 0915 h     | 71 ± 2   | 125 ± 4    | 69 ± 3     | 69 ± 2   | 111 ± 3    | 57 ± 2     | 90 ± 3   | 111 ± 3    | 62 ± 2     |
| 0930 h     | 72 ± 3   | 124 ± 4    | 68 ± 3     | 67 ± 2   | 110 ± 3    | 57 ± 2     | 86 ± 3   | 113 ± 3    | 60 ± 2     |
| 0945 h     | 73 ± 3   | 123 ± 4    | 65 ± 3     | 67 ± 2   | 110 ± 3    | 55 ± 2     | 82 ± 3   | 110 ± 3    | 58 ± 2     |
| 1000 h     | 76 ± 3   | 126 ± 4    | 64 ± 2     | 66 ± 2   | 108 ± 2    | 53 ± 1     | 82 ± 2   | 109 ± 3    | 57 ± 2     |
| 1015 h     | 73 ± 2   | 125 ± 3    | 63 ± 3     | 66 ± 2   | 109 ± 3    | 52 ± 2     | 86 ± 2   | 109 ± 3    | 55 ± 2     |
| 1030 h     | 73 ± 2   | 122 ± 4    | 61 ± 3     | 63 ± 2   | 105 ± 3    | 52 ± 1     | 84 ± 2   | 106 ± 3    | 53 ± 2     |
| 1045 h     | 72 ± 3   | 122 ± 4    | 60 ± 2     | 60 ± 2   | 106 ± 3    | 51 ± 1     | 80 ± 2   | 106 ± 3    | 51 ± 2     |
| 1145 h     | 73 ± 3   | 119 ± 4    | 60 ± 2     | 60 ± 2   | 106 ± 3    | 51 ± 1     | 77 ± 2   | 105 ± 3    | 51 ± 2     |

Values are mean ± SE. dBP, diastolic blood pressure; HR, heart rate; sBP, systolic blood pressure. PTL, phentolamine; PRP, propranolol.

**FIG. 4.** Mean ± SE plasma epinephrine, norepinephrine, and pancreatic polypeptide concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (PTL + PRP, ▲), or phentolamine plus propranolol with atropine (PTL + PRP + Atropine, △) during the clamps on day 1. The P values represent comparisons with the values during saline infusion on day 1 (○), P < 0.0001 for epinephrine and norepinephrine on day 2 (●), and P < 0.0001 for pancreatic polypeptide under all three conditions on day 2 (●, ▲, and △).

**FIG. 5.** Mean ± SE plasma insulin, glucagon, growth hormone, and cortisol concentrations are shown during morning hyperinsulinemic euglycemic and hypoglycemic clamps on day 1 with saline infusion (○) and on day 2 after saline (●), phentolamine plus propranolol (▲), or phentolamine plus propranolol with atropine (△) during the clamps on day 1. The P values represent comparisons with the values during saline on day 1 (○); see text for details.
sympathoadrenal response to subsequent hypoglycemia. The latter is the key feature of HAAF in diabetes (1–8).

The data do not disclose—but do not categorically exclude—an additional cholinergic mechanism. The sympathoadrenal response to hypoglycemia on day 2 was similar whether the muscarinic cholinergic antagonist atropine was or was not administered with phentolamine and propranolol during hypoglycemia on day 1.

Morning and afternoon hypoglycemia with saline infusion on day 1 also led to attenuated increments in the plasma pancreatic polypeptide concentration, a marker of the parasympathetic response to hypoglycemia (18), during hypoglycemia on day 2. In contrast to the effect on the sympathoadrenal response, adrenergic blockade (without or with cholinergic blockade) during hypoglycemia on day 1 did not prevent the attenuated pancreatic polypeptide response to hypoglycemia on day 2. An altered parasympathetic response is not known to be involved in the pathogenesis of HAAF in diabetes (1).

To the extent the drugs used enter the central nervous system (propranolol and atropine are known to do so), the data do not distinguish between central and peripheral (autonomic) nervous system mediation of the effect of antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia. However, because the adrenergic antagonists block the heart rate and pressor responses to hypoglycemia, which are normally mediated by the autonomic response, one might speculate that it was blockade of adrenergic sympathoadrenal actions during hypoglycemia on day 1 that prevented an attenuated plasma catecholamine response to hypoglycemia on day 2.

The data confirm substantially higher plasma epinephrine and norepinephrine concentrations in response to hypoglycemia during adrenergic blockade on day 1 (15). That is expected because both catecholamines are cleared through β-adrenergic mechanisms in humans (19). (Given the short half-times of the antagonists and the catecholamines, a carry-over effect to the next day is unlikely.) The current findings of higher plasma concentrations of infused insulin and of endogenous growth hormone and cortisol during hypoglycemia during adrenergic blockade suggest that adrenergic mechanisms are also involved in the clearance of these hormones. The growth hormone responses to hypoglycemia, like the epinephrine and norepinephrine responses, were reduced after hypoglycemia with saline infusion but not after hypoglycemia with adrenergic blockade (without or with cholinergic blockade). An interesting finding was that the pancreatic polypeptide, glucagon, and cortisol responses to hypoglycemia were reduced on day 2 regardless of the day 1 conditions. Among these, a reduced glucagon response is a feature of HAAF (1). Thus, the data further support the view that the mechanisms of the reduced glucagon and epinephrine responses to hypoglycemia in HAAF are different (1).

In conclusion, the data indicate that adrenergic mechanisms mediate the effect of recent antecedent hypoglycemia to reduce the sympathoadrenal response to subsequent hypoglycemia, the key feature of HAAF in diabetes, in humans.

ACKNOWLEDGMENTS

This study was partly supported by National Institutes of Health Grants R37-DK-27085 and ULI-RR-24992 and by a fellowship award from the American Diabetes Association.

P.E.C. has served as a consultant to Bristol-Myers Squibb/ AstraZeneca, MannKind Corp., Merck & Co., and Novo Nordisk in the past year. No other potential conflicts of interest relevant to this article were reported.

R.R. and P.E.C. designed the study, R.R. conducted it, and R.R. and P.E.C. analyzed the data and wrote the manuscript.

The authors acknowledge the assistance of the following Washington University staff: Licia Rowe, Laura Karsteter, Nilima Parikh, Tanya Eden, Shirley Frei, Janice Bathon, Paula Blood, and David Gibson of the Clinical Research Unit and of the Core Laboratory for Clinical Studies; the technical assistance of Krishan Jethi, MS; and the statistical assistance of Ling Chen, PhD, MPH. Janet Dedeke prepared this manuscript.

REFERENCES

1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:2169–2176
2. Heller SR, Cryer PE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in non-diabetic humans. Diabetes 1991;40:222–228
3. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993;91:819–828
4. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002;51:724–733
5. Fanelli CG, Epifano L, Rambatti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683–1689
6. Fanelli C, Pampaloni S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994;37:1265–1270
7. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283–287
8. Dagogo-Jack S, Rattasaro C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994;43:1426–1434
9. Sherwin RS. Bringing light to the dark side of insulin: a journey across the blood-brain barrier. Diabetes 2005;54:2259–2268
10. Dunn JT, Cranston I, Marsden PK, Amiel SA, Reed LJ. Attenuation of amygdala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycaemia unawareness? Diabetes 2007;56:2766–2773
11. Teves D, Viden TO, Cryer PE, Powers WJ. Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci USA 2004;101:6217–6221
12. Arbelaz AM, Powers WJ, Viden TO, Price JL, Cryer PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008;57:470–475
13. Sjärne L. Catecholaminergic neurotransmission: flagship of all neurobiol. Acta Physiol Scand 1999;166:251–259
14. Bloom FE. The catecholamine neuron: historical and future perspectives. Prog Neurobiol 2010;90:75–81
15. Towler DA, Havlin CE, Craft S, Cryer PE. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neurogenic symptoms in diabetes. Diabetes 1993;42:1791–1708
16. Shah SD, Clutter WE, Cryer PE. External and internal standards in the single-isotope derivative (radioenzymatic) measurement of plasma nor-epinephrine and epinephrine. J Lab Clin Med 1985;106:624–629
17. DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenergic system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004; 287:E32–E41
18. Schwartz TW. Pancreatic polypeptide: a hormone under vagnal control. Gastroenterology 1983;85:1411–1425
19. Cryer PE, Rizza RA, Haymond MW, Gerich JE. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism 1980;29(Suppl. 1):1114–1118